New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25158083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jeetendra Kumar Nag und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sharett Institute of Oncology, Hadassah Medical Center, Hebrew University, Jerusalem 91120, Israel. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Science Foundation.
Abstract (Originalsprache)
Cancer cells depend on specific oncogenic pathways or present a genetic alteration that leads to a particular disturbance. Still, personalized and targeted biological therapy remains challenging, with current efforts generally yielding disappointing results. Carefully assessing onco-target molecular pathways can, however, potently assist with such efforts for the selection of patient populations that would best respond to a given drug treatment. RNF43, an E3 ubiquitin ligase that negatively regulates Wnt/frizzled (FZD) receptors by their ubiquitination, internalization, and degradation, controls a key pathway in cancer. Recently, additional target proteins of RNF43 were described, including p85 of the PI3K/AKT/mTOR signaling pathway and protease-activated receptor 2 (PAR2), a G-protein-coupled receptor that potently induces β-catenin stabilization, independent of Wnts. RNF43 mutations with impaired E3 ligase activity were found in several types of cancers (e.g., gastrointestinal system tumors and endometrial and ovarian cancer), pointing to a high dependency on FZD receptors and possibly PAR2 and the PI3K/AKT/mTOR signaling pathway. The development of drugs toward these targets is essential for improved treatment of cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sharett Institute of Oncology, Hadassah Medical Center, Hebrew University, Jerusalem 91120, Israel.
ORCID-Profile: Shoshana Sedley, Rachel Bar-Shavit
Förderung
- Israel Science Foundation
Zitieren
APA
Nag, J. K., Appasamy, P., Malka, H., Sedley, S., & Bar-Shavit, R. (2024). New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158083
Vancouver
Nag JK, Appasamy P, Malka H, Sedley S, Bar-Shavit R. New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158083
BibTeX
@article{Nag2024,
author = {Nag, Jeetendra Kumar and Appasamy, Priyanga and Malka, Hodaya and Sedley, Shoshana and Bar-Shavit, Rachel},
title = {New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25158083}
}
EUVIMED